Rare disease specialist Spectrum eyes potential $2B-plus sale: Bloomberg
admin 27th June 2018 Uncategorised 0Biopharma M&A has picked up this year with deals worth more than $34 billion so far, not counting Takeda’s $62 billion offer for Shire. Now, the much smaller Spectrum Pharmaceuticals—with six marketed drugs and $116 million in 2017 sales—is testing the waters, Bloomberg says.
More: Rare disease specialist Spectrum eyes potential B-plus sale: Bloomberg
Source: fierce